Sulfamoyl benzamide derivatives and methods of their use

Details Sulfamoyl benzamide derivatives and methods of their use Sulfamoyl benzamide derivatives and methods of their use

2007-11-20

2007-11-20

Richter, Johann (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S086000, C546S317000, C514S602000, C514S319000

Reexamination Certificate

active

11251160

ABSTRACT:
Novel sulfamoyl benzamide compounds, pharmaceutical compositions containing the sulfamoyl benzamide compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the sulfamoyl benzamide compounds are agonists and/or modulating ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, inflammation, auto-immune diseases, ischemic conditions, immune-related disorders, hypertension, neurological disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, for inhibiting mechanical hyperalgesia associated with nerve injury, and as an appetite stimulant.

REFERENCES:
patent: 3565920 (1971-02-01), Werner
patent: 6228808 (2001-05-01), Kehne et al.
patent: 0 659 748 (2000-07-01), None
patent: 1328169 (1973-08-01), None
patent: 2 295 616 (1996-06-01), None
patent: WO 03/087061 (2003-10-01), None
patent: WO 2004/017920 (2004-03-01), None
patent: WO 2004/018414 (2004-03-01), None
Kushner et al., Anticonvulsants. N-Benzylamides, J. Org. Chem.; 1951; 16(8); 1283-1288.
Bhargava, H.N., et al., “Effect of nitric oxide synthases inhibition on tolerance to the analgesic action of D-Pen2, D-Pen5enkephalin and morphine in the mouse,”Neuropeptides, 1996, 30(3), 219-223.
Bilsky, E.J., et al., “Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice,”J. Pharmacol. Exp. Ther., 1996, 277(1), 484-490.
Cheng, Y.-C., et al., “Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction,”Biochem. Pharmacol., 1973, 22, 3099-3108.
Compton, D.R., et al., “Cannabinoid behaviors: specific versus nonspecific actions,”Marijuana: An International Research Report, 1987, 7, 213-218.
DeLean, A.P., et al., “Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves,”Am. J. Physiol., 1978, 235, E97-E102.
Dixon, W.J., “Efficient analysis of experimental observations,”Ann. Rev. Pharmacol. Toxicol., 1980, 20, 441-462.
Dourish, C.T., et al., “Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718,”Eur. J. Pharmacol., 1988, 147, 469-472.
Duan, J., et al., “Trifluoromethylation of organic halides with methyl halodifluoroacetates—a process via difluorocarbene and trifluoromethide intermediates,”J. of Fluorine Chemistry, 1993, 61, 279-284.
Gill, E.W., et al., “Brain levels of Δ1-tetrahydrocannabinol and its metabolites in mice-correlation with behaviour, and the effect of the metabolic inhibitors SKF 525A and piperonyl butoxide,”Biochem. Pharmacol., 1972, 21, 2237-2248.
Gill, E.W., et al., “Preliminary experiments on the chemistry and pharmacology of cannabis,”Nature, 1970, 228, 134-136.
Greene, T.W., et al., :Protection for the hydroxyl group, including 1,2- and 1,3-diols,Protective Groups in Organic Synthesis, 3rdEd.,Wiley&Sons, 1991, Chapter 2, 10-123.
Howlett, A.C., et al., “International union of pharmacology. XXVII.. Classification of cannabinoid receptors,”Pharmacological Reviews, 2002, 54(2), 161-202.
Idris, A.I., et al., “Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors,”Nature Medicine, 2005, 11(7), 774-779.
Iwamura, H., et al., “In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2receptor,”J. Pharm. Exp. Ther., 2001, 296(2), 420-425.
Jain, K.K., “A guide to drug evaluation for chronic pain,”Emerging Drugs, 2000, 5(2), 241-257.
Kim, S.H., et al., “An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat,”Pain, 1992, 50, 355-363.
LaBuda, C.J., et al., “Enhanced formalin nociceptive responses following L5 nerve ligation in the rat reveals neuropathy-induced inflammatory hyperalgesia,”Pain, 2001, 94, 59-63.
LaBuda, C.J., et al., “Morphine and gabapentin decrease mechanical hyperalgesia and escape/avoidance behavior in a rat model of neuropathic pain,”Neurosci. Letts., 2000, 290, 137-140.
LaBuda, C.J., et al., “A behavioral test paradigm to measure the aversive quality of inflammatory and neuropathic pain in rats,”Exp. Neurol., 2000, 163, 490-494.
Lavey, B.J., et al., “Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies,”Bioorg.&Med. Chem. Lett, 2005, 15, 783-786.
Lunn, C.A., et al., “Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial biological characterization,” ICRS 15thAnnual Symposium of the Cannabinoids, Clearwater Beach, FL, Jun. 24-27, 2005, p. 3.
Malan, T.P., Jr., et al., “CB2cannabinoid receptor agonists: pain relief without psychoactive effects?,”Curr. Opin. Pharm., 2003, 3, 62-67.
Mao, M.J., et al., “Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats,”Pain, 1996, 67, 361-368.
Mechoulam, R., “Cannabinoids as therapeutic agents,”CRC Press, Boca Raton, FL, 1986, 1-19.
Nichols, M.L., et al., “Enhancement of the antiallodynic and antinociceptive efficacy of spinal morphine by antisera to dynorphin A (1-13) or MK-801 in a nerve-ligation model of peripheral neuropathy,”Pain, 1997, 69, 317-322.
Parolaro, D., “Presence and functional regulations of cannabinoid receptors in immune cells,”Life Sci., 1999, 65(6/7), 637-644.
Pertwee, R.B., “Pharmacology of cannabinoid receptor ligands,”Current Medicinal Chem., 1999, 6, 635-664.
Pertwee, R.G., “The ring test: a quantitative method for assessing the ‘cataleptic’, effect of cannabis in mice,”Br. J. Pharmacology, 1972, 46, 753-763.
Pertwee, R.G., “Cannabinoid receptors and pain,”Prog. in Neurobiol., 2001, 63, 569-611.
Rice, A.S., “Cannabinoids and pain,”Curr. Opin. Investig. Drugs, 2001, 2(3), 399-414.
Rinaldi-Carmona, M., et al., “SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor,”J. of Pharmacology&Experimental Therapeutics, 1998, 284(2), 644-650.
Yang, C., et al., “Palladium-catalyzed cyanation of aryl bromides promoted by low-level organotin compounds,”Organic Letts., 2004, 6(17), 2837-2840.

Affiliated with

Also associated with

Rating

Sulfamoyl benzamide derivatives and methods of their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfamoyl benzamide derivatives and methods of their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfamoyl benzamide derivatives and methods of their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3888272